Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Scientific advisors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: Publication

    Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC

    Adrian von Witzleben, et al. Front Oncol., January 26 2021 – Read the article Publication

    Published 26 January 2021
    Categorized as 2021, Publication, TG4001, TG4001

    Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs

    Jérémy Béguin, et al. Sci Rep., January 26 2021 – Read the article Publication

    Published 26 January 2021
    Categorized as 2021, Publication, TG6002

    Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators

    Franck Gallardo, et al. Biomedicines, November 26 2020 – Read the article Publication

    Published 26 November 2020
    Categorized as 2020, Invir.IO, Publication

    BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment

    Poster BT-001 M. Semmrich et al. SITC 2020 Download the poster here Poster Presentation

    Published 9 November 2020
    Categorized as 2020, BT-001, BT-001 (EN), Invir.IO, Publication, publication HP en

    TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity

    Poster SITC TG4001 C. Le Tourneau et al. SITC 2020 Download the poster here Poster Presentation

    Published 9 November 2020
    Categorized as 2020, Publication, publication HP en, TG4001

    High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma

    Tiphaine Delaunay, et al. Molecular Therapy Oncolytics, September 2020 – Read the article and view videos Publication

    Published 25 September 2020
    Categorized as 2020, Invir.IO, Publication, TG6002, TG6002

    Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer

    Jérémy Béguin, et al. Molecular Therapy Oncolytics, September 2020 – Read the article Publication

    Published 2 September 2020
    Categorized as 2020, Publication, TG6002, TG6002

    Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs

    Jérémy Béguin, et al. BMC Vet Res., August 25 2020 – Read the article Publication

    Published 25 August 2020
    Categorized as 2020, Publication, TG6002, TG6002

    Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine

    Poster EUROoCS H. Le et al. EUROoCS 2020 Download the poster here Poster Presentation

    Published 8 July 2020
    Categorized as 2020, Publication

    Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine

    AACR2020 myvac B. Mallone et al. AACR 2020 Download the poster here Poster Presentation

    Published 22 June 2020
    Categorized as 2020, Myvac, Publication, publication HP en, TG4050

    Posts navigation

    Newer posts Page 1 Page 2 … Page 9 Older posts
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo